{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:16:08Z","timestamp":1792887368793,"version":"4.5.0"},"reference-count":173,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["MJFF-024348"],"award-info":[{"award-number":["MJFF-024348"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016964","name":"Werner Siemens-Stiftung","doi-asserted-by":"publisher","award":["Werner Siemens-Stiftung"],"award-info":[{"award-number":["Werner Siemens-Stiftung"]}],"id":[{"id":"10.13039\/100016964","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014405","name":"Centre for Addiction and Mental Health Foundation","doi-asserted-by":"publisher","award":["Discovery fund and womenmind"],"award-info":[{"award-number":["Discovery fund and womenmind"]}],"id":[{"id":"10.13039\/100014405","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005155","name":"Azrieli Foundation","doi-asserted-by":"publisher","award":["Azrieli Foundation"],"award-info":[{"award-number":["Azrieli Foundation"]}],"id":[{"id":"10.13039\/501100005155","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","award":["Tier 1"],"award-info":[{"award-number":["Tier 1"]}],"id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00259-025-07695-0","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T01:52:58Z","timestamp":1768960378000},"page":"4211-4239","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["PET imaging of alpha-synuclein: from radiotracer design through in vitro and in vivo translation"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8207-3358","authenticated-orcid":false,"given":"Anna","family":"Pees","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2717-0723","authenticated-orcid":false,"given":"Ann-Kathrin","family":"Grotegerd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2216-2524","authenticated-orcid":false,"given":"Daniel","family":"Bleher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0231-7717","authenticated-orcid":false,"given":"Kristina","family":"Herfert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2087-5125","authenticated-orcid":false,"given":"Neil","family":"Vasdev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"7695_CR1","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","volume":"186","author":"DM Wilson III","year":"2023","unstructured":"Wilson DM III, Cookson MR, Van Den Bosch L, Zetterberg H, Holtzman DM, Dewachter I. Hallmarks of neurodegenerative diseases. Cell. 2023;186:693\u2013714. https:\/\/doi.org\/10.1016\/j.cell.2022.12.032.","journal-title":"Cell"},{"key":"7695_CR2","doi-asserted-by":"publisher","first-page":"112","DOI":"10.4161\/pri.2.3.7488","volume":"2","author":"RN Rambaran","year":"2008","unstructured":"Rambaran RN, Serpell LC. Amyloid fibrils: abnormal protein assembly. Prion. 2008;2:112\u20137. https:\/\/doi.org\/10.4161\/pri.2.3.7488.","journal-title":"Prion"},{"key":"7695_CR3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nrn2786","volume":"11","author":"B Frost","year":"2010","unstructured":"Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci. 2010;11:155\u20139. https:\/\/doi.org\/10.1038\/nrn2786.","journal-title":"Nat Rev Neurosci"},{"key":"7695_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2019.134316","volume":"709","author":"MX Henderson","year":"2019","unstructured":"Henderson MX, Trojanowski JQ, Lee VMY. \u03b1-Synuclein pathology in Parkinson\u2019s disease and related \u03b1-synucleinopathies. Neurosci Lett. 2019;709:134316. https:\/\/doi.org\/10.1016\/j.neulet.2019.134316.","journal-title":"Neurosci Lett"},{"key":"7695_CR5","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/jnc.14965","volume":"153","author":"IC Br\u00e1s","year":"2020","unstructured":"Br\u00e1s IC, Dominguez-Meijide A, Gerhardt E, Koss D, L\u00e1zaro DF, Santos PI, et al. Synucleinopathies: where we are and where we need to go. J Neurochem. 2020;153:433\u201354. https:\/\/doi.org\/10.1111\/jnc.14965.","journal-title":"J Neurochem"},{"key":"7695_CR6","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.bbapap.2019.03.001","volume":"1867","author":"S Mehra","year":"2019","unstructured":"Mehra S, Sahay S, Maji SK. \u03b1-Synuclein misfolding and aggregation: implications in parkinson\u2019s disease pathogenesis. Biochim Et Biophys Acta (BBA) - Proteins Proteom. 2019;1867:890\u2013908. https:\/\/doi.org\/10.1016\/j.bbapap.2019.03.001.","journal-title":"Biochim Et Biophys Acta (BBA) - Proteins Proteom"},{"key":"7695_CR7","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s12031-011-9632-1","volume":"45","author":"AJ Espay","year":"2011","unstructured":"Espay AJ, Litvan I. Parkinsonism and frontotemporal dementia: the clinical overlap. J Mol Neurosci. 2011;45:343\u20139. https:\/\/doi.org\/10.1007\/s12031-011-9632-1.","journal-title":"J Mol Neurosci"},{"key":"7695_CR8","doi-asserted-by":"publisher","DOI":"10.20900\/agmr20250013","volume":"7","author":"L Massoni","year":"2025","unstructured":"Massoni L. Neuropsychiatric symptoms of Alzheimer disease, Parkinson disease and Lewy body dementia: genetic, clinical and therapeutic overlaps. Adv Geriatr Med Res. 2025;7:e250013. https:\/\/doi.org\/10.20900\/agmr20250013.","journal-title":"Adv Geriatr Med Res"},{"key":"7695_CR9","doi-asserted-by":"publisher","first-page":"e0000107","DOI":"10.1371\/journal.pmen.0000107","volume":"1","author":"L McCormick","year":"2024","unstructured":"McCormick L, Bodla AP, Rubin RT. Very early onset dementias: importance of differentiating from schizophrenia spectrum disorders. PLoS Ment Health. 2024;1:e0000107. https:\/\/doi.org\/10.1371\/journal.pmen.0000107.","journal-title":"PLoS Ment Health"},{"key":"7695_CR10","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41591-024-03469-7","volume":"31","author":"C Soto","year":"2025","unstructured":"Soto C, Mollenhauer B, Hansson O, Kang UJ, Alcalay RN, Standaert D, et al. Toward a biological definition of neuronal and glial synucleinopathies. Nat Med. 2025;31:396\u2013408. https:\/\/doi.org\/10.1038\/s41591-024-03469-7.","journal-title":"Nat Med"},{"key":"7695_CR11","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","volume":"23","author":"T Simuni","year":"2024","unstructured":"Simuni T, Chahine LM, Poston K, Brumm M, Buracchio T, Campbell M, et al. A biological definition of neuronal \u03b1-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 2024;23:178\u201390. https:\/\/doi.org\/10.1016\/S1474-4422(23)00405-2.","journal-title":"Lancet Neurol"},{"key":"7695_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36377-4","volume":"14","author":"J Rong","year":"2023","unstructured":"Rong J, Haider A, Jeppesen TE, Josephson L, Liang SH. Radiochemistry for positron emission tomography. Nat Commun. 2023;14:3257. https:\/\/doi.org\/10.1038\/s41467-023-36377-4.","journal-title":"Nat Commun"},{"key":"7695_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/cpt.132","volume":"98","author":"R Hargreaves","year":"2015","unstructured":"Hargreaves R, Hoppin J, Sevigny J, Patel S, Chiao P, Klimas M, et al. Optimizing central nervous system drug development using molecular imaging. Clin Pharmacol Ther. 2015;98:47\u201360. https:\/\/doi.org\/10.1002\/cpt.132.","journal-title":"Clin Pharmacol Ther"},{"key":"7695_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ph14090847","author":"\u0160 Korat","year":"2021","unstructured":"Korat \u0160, Bidesi NSR, Bonanno F, Di Nanni A, Ho\u00e0ng ANN, Herfert K, et al. Alpha-synuclein PET tracer development-an overview about current efforts. Pharmaceuticals (Basel). 2021. https:\/\/doi.org\/10.3390\/ph14090847.","journal-title":"Pharmaceuticals (Basel)"},{"key":"7695_CR15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s12272-025-01538-0","volume":"48","author":"MM Alam","year":"2025","unstructured":"Alam MM, Lee SH, Wasim S, Lee SY. PET tracer development for imaging alpha-synucleinopathies. Arch Pharm Res. 2025;48:333\u201350. https:\/\/doi.org\/10.1007\/s12272-025-01538-0.","journal-title":"Arch Pharm Res"},{"key":"7695_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-024-00787-9","volume":"20","author":"J Xiang","year":"2025","unstructured":"Xiang J, Zhang Z, Wu S, Ye K. Positron emission tomography tracers for synucleinopathies. Mol Neurodegener. 2025;20:1. https:\/\/doi.org\/10.1186\/s13024-024-00787-9.","journal-title":"Mol Neurodegener"},{"key":"7695_CR17","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, Tredici KD, R\u00fcb U, Vos RAId, Steur ENHJ, Braak E. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging. 2003;24:197\u2013211.","journal-title":"Neurobiol Aging"},{"key":"7695_CR18","doi-asserted-by":"publisher","first-page":"1255555","DOI":"10.1126\/science.1255555","volume":"349","author":"M Goedert","year":"2015","unstructured":"Goedert M. Alzheimer\u2019s and parkinson\u2019s diseases: the prion concept in relation to assembled A\u03b2, tau, and \u03b1-synuclein. Science. 2015;349:1255555. https:\/\/doi.org\/10.1126\/science.1255555.","journal-title":"Science"},{"key":"7695_CR19","doi-asserted-by":"publisher","first-page":"12185","DOI":"10.1021\/acs.jmedchem.3c00779","volume":"66","author":"HY Kim","year":"2023","unstructured":"Kim HY, Chia WK, Hsieh CJ, Saturnino Guarino D, Graham TJA, Lengyel-Zhand Z, et al. A novel brain PET radiotracer for imaging alpha synuclein fibrils in multiple system atrophy. J Med Chem. 2023;66:12185\u2013202. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c00779.","journal-title":"J Med Chem"},{"key":"7695_CR20","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1016\/j.cell.2023.06.004","volume":"186","author":"J Xiang","year":"2023","unstructured":"Xiang J, Tao Y, Xia Y, Luo S, Zhao Q, Li B, et al. Development of an \u03b1-synuclein positron emission tomography tracer for imaging synucleinopathies. Cell. 2023;186:3350\u2013e6719. https:\/\/doi.org\/10.1016\/j.cell.2023.06.004.","journal-title":"Cell"},{"key":"7695_CR21","doi-asserted-by":"publisher","unstructured":"Saw RS, Haas S, Schmidt F, Ryazanov S, Leonov A, Kuebler L et al. [11\u00a0C]MODAG-005 \u2013 a novel PET tracer targeting alpha-synuclein aggregates in the brain. 2024. https:\/\/doi.org\/10.21203\/rs.3.rs-2189800\/v1.","DOI":"10.21203\/rs.3.rs-2189800\/v1"},{"key":"7695_CR22","doi-asserted-by":"publisher","first-page":"102788","DOI":"10.1016\/j.xpro.2023.102788","volume":"5","author":"J Xiang","year":"2024","unstructured":"Xiang J, Xia Y, Luo S, Zhang Z, Ye K. Protocol for screening \u03b1-synuclein PET tracer candidates in vitro and ex vivo. STAR Protoc. 2024;5:102788. https:\/\/doi.org\/10.1016\/j.xpro.2023.102788.","journal-title":"STAR Protoc"},{"key":"7695_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/biom11101419","author":"S Mehra","year":"2021","unstructured":"Mehra S, Gadhe L, Bera R, Sawner AS, Maji SK. Structural and functional insights into \u03b1-synuclein fibril polymorphism. Biomolecules. 2021. https:\/\/doi.org\/10.3390\/biom11101419.","journal-title":"Biomolecules"},{"key":"7695_CR24","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3233\/jpd-171248","volume":"8","author":"NK Polinski","year":"2018","unstructured":"Polinski NK, Volpicelli-Daley LA, Sortwell CE, Luk KC, Cremades N, Gottler LM, et al. Best practices for generating and using Alpha-Synuclein pre-formed fibrils to model Parkinson\u2019s disease in rodents. J Parkinsons Dis. 2018;8:303\u201322. https:\/\/doi.org\/10.3233\/jpd-171248.","journal-title":"J Parkinsons Dis"},{"key":"7695_CR25","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3233\/jpd-240228","volume":"14","author":"AL Woerman","year":"2024","unstructured":"Woerman AL, Luk KC. Are preformed fibrils a model of parkinson\u2019s disease? J Parkinsons Dis. 2024;14:1095\u2013103. https:\/\/doi.org\/10.3233\/jpd-240228.","journal-title":"J Parkinsons Dis"},{"key":"7695_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/978-1-60761-744-0_2","volume":"670","author":"WB Stine","year":"2011","unstructured":"Stine WB, Jungbauer L, Yu C, LaDu MJ. Preparing synthetic A\u03b2 in different aggregation States. Methods Mol Biol. 2011;670:13\u201332. https:\/\/doi.org\/10.1007\/978-1-60761-744-0_2.","journal-title":"Methods Mol Biol"},{"key":"7695_CR27","doi-asserted-by":"publisher","first-page":"7038","DOI":"10.1021\/bi500792f","volume":"53","author":"EA Yates","year":"2014","unstructured":"Yates EA, Legleiter J. Preparation protocols of A\u03b2(1\u201340) promote the formation of polymorphic aggregates and altered interactions with lipid bilayers. Biochemistry. 2014;53:7038\u201350. https:\/\/doi.org\/10.1021\/bi500792f.","journal-title":"Biochemistry"},{"key":"7695_CR28","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41593-023-01341-4","volume":"26","author":"ST Kumar","year":"2023","unstructured":"Kumar ST, Nazarov S, Porta S, Maharjan N, Cendrowska U, Kabani M, et al. Seeding the aggregation of TDP-43 requires post-fibrillization proteolytic cleavage. Nat Neurosci. 2023;26:983\u201396. https:\/\/doi.org\/10.1038\/s41593-023-01341-4.","journal-title":"Nat Neurosci"},{"key":"7695_CR29","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1038\/s41467-022-30585-0","volume":"13","author":"AJ Dregni","year":"2022","unstructured":"Dregni AJ, Duan P, Xu H, Changolkar L, El Mammeri N, Lee VMY, et al. Fluent molecular mixing of Tau isoforms in Alzheimer\u2019s disease neurofibrillary tangles. Nat Commun. 2022;13:2967. https:\/\/doi.org\/10.1038\/s41467-022-30585-0.","journal-title":"Nat Commun"},{"key":"7695_CR30","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/s41586-022-05319-3","volume":"610","author":"Y Yang","year":"2022","unstructured":"Yang Y, Shi Y, Schweighauser M, Zhang X, Kotecha A, Murzin AG, et al. Structures of \u03b1-synuclein filaments from human brains with lewy pathology. Nature. 2022;610:791\u20135. https:\/\/doi.org\/10.1038\/s41586-022-05319-3.","journal-title":"Nature"},{"key":"7695_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.104566","volume":"299","author":"C Sun","year":"2023","unstructured":"Sun C, Zhou K, DePaola Pt, Shin WS, Hillyer T, Sawaya MR, et al. Cryo-EM structure of amyloid fibril formed by \u03b1-synuclein hereditary A53E mutation reveals a distinct protofilament interface. J Biol Chem. 2023;299:104566. https:\/\/doi.org\/10.1016\/j.jbc.2023.104566.","journal-title":"J Biol Chem"},{"key":"7695_CR32","doi-asserted-by":"publisher","first-page":"6866","DOI":"10.1073\/pnas.1916176117","volume":"117","author":"U Cendrowska","year":"2020","unstructured":"Cendrowska U, Silva PJ, Ait-Bouziad N, M\u00fcller M, Guven ZP, Vieweg S, et al. Unraveling the complexity of amyloid polymorphism using gold nanoparticles and cryo-EM. Proc Natl Acad Sci U S A. 2020;117:6866\u201374. https:\/\/doi.org\/10.1073\/pnas.1916176117.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7695_CR33","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adq3539","volume":"10","author":"A Sokratian","year":"2024","unstructured":"Sokratian A, Zhou Y, Tatli M, Burbidge KJ, Xu E, Viverette E, et al. Mouse \u03b1-synuclein fibrils are structurally and functionally distinct from human fibrils associated with Lewy body diseases. Sci Adv. 2024;10:eadq3539. https:\/\/doi.org\/10.1126\/sciadv.adq3539.","journal-title":"Sci Adv"},{"key":"7695_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232315036","volume":"23","author":"KB Varshavskaya","year":"2022","unstructured":"Varshavskaya KB, Mitkevich VA, Makarov AA, Barykin EP. Synthetic, cell-derived, brain-derived, and recombinant \u03b2-amyloid: modelling Alzheimer\u2019s disease for research and drug development. Int J Mol Sci. 2022;23:15036. https:\/\/doi.org\/10.3390\/ijms232315036.","journal-title":"Int J Mol Sci"},{"key":"7695_CR35","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41586-020-2317-6","volume":"585","author":"M Schweighauser","year":"2020","unstructured":"Schweighauser M, Shi Y, Tarutani A, Kametani F, Murzin AG, Ghetti B, et al. Structures of \u03b1-synuclein filaments from multiple system atrophy. Nature. 2020;585:464\u20139. https:\/\/doi.org\/10.1038\/s41586-020-2317-6.","journal-title":"Nature"},{"key":"7695_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2025.106820","volume":"206","author":"L Fielding","year":"2025","unstructured":"Fielding L, Menard MA, Roth J, Iuliano M, Dehay B, Aguilar-Calvo P, et al. Current safety recommendations for handling mouse and human \u03b1synuclein pre-formed fibrils. Neurobiol Dis. 2025;206:106820. https:\/\/doi.org\/10.1016\/j.nbd.2025.106820.","journal-title":"Neurobiol Dis"},{"key":"7695_CR37","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/s41589-024-01551-2","volume":"20","author":"AT Balana","year":"2024","unstructured":"Balana AT, Mahul-Mellier A-L, Nguyen BA, Horvath M, Javed A, Hard ER, et al. O-GlcNAc forces an \u03b1-synuclein amyloid strain with notably diminished seeding and pathology. Nat Chem Biol. 2024;20:646\u201355. https:\/\/doi.org\/10.1038\/s41589-024-01551-2.","journal-title":"Nat Chem Biol"},{"key":"7695_CR38","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1038\/s41467-024-46898-1","volume":"15","author":"J Hu","year":"2024","unstructured":"Hu J, Xia W, Zeng S, Lim Y-J, Tao Y, Sun Y, et al. Phosphorylation and O-GlcNAcylation at the same \u03b1-synuclein site generate distinct fibril structures. Nat Commun. 2024;15:2677. https:\/\/doi.org\/10.1038\/s41467-024-46898-1.","journal-title":"Nat Commun"},{"key":"7695_CR39","doi-asserted-by":"publisher","first-page":"907293","DOI":"10.3389\/fnagi.2022.907293","volume":"14","author":"MK Just","year":"2022","unstructured":"Just MK, Gram H, Theologidis V, Jensen PH, Nilsson KPR, Lindgren M, et al. Alpha-synuclein strain variability in body-first and brain-first synucleinopathies. Front Aging Neurosci. 2022;14:907293. https:\/\/doi.org\/10.3389\/fnagi.2022.907293.","journal-title":"Front Aging Neurosci"},{"key":"7695_CR40","doi-asserted-by":"publisher","first-page":"6810","DOI":"10.1038\/s41467-022-34552-7","volume":"13","author":"B Frieg","year":"2022","unstructured":"Frieg B, Antonschmidt L, Dienemann C, Geraets JA, Najbauer EE, Matthes D, et al. The 3D structure of lipidic fibrils of \u03b1-synuclein. Nat Commun. 2022;13:6810. https:\/\/doi.org\/10.1038\/s41467-022-34552-7.","journal-title":"Nat Commun"},{"key":"7695_CR41","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/jnen\/nlae053","volume":"83","author":"DH Oakley","year":"2024","unstructured":"Oakley DH, Chung M, Abrha S, Hyman BT, Frosch MP. \u03b2-Amyloid species production and Tau phosphorylation in iPSC-neurons with reference to neuropathologically characterized matched donor brains. J Neuropathol Exp Neurol. 2024;83:772\u201382. https:\/\/doi.org\/10.1093\/jnen\/nlae053.","journal-title":"J Neuropathol Exp Neurol"},{"key":"7695_CR42","doi-asserted-by":"publisher","unstructured":"Lee SS, Civitelli L, Parkkinen L. Brain-derived and in vitro-seeded alpha-synuclein fibrils exhibit distinct biophysical profiles. 2024. https:\/\/doi.org\/10.7554\/elife.92775.2.","DOI":"10.7554\/elife.92775.2"},{"key":"7695_CR43","doi-asserted-by":"publisher","DOI":"10.3791\/55835","author":"I Diner","year":"2017","unstructured":"Diner I, Nguyen T, Seyfried NT. Enrichment of detergent-insoluble protein aggregates from human postmortem brain. J Vis Exp. 2017. https:\/\/doi.org\/10.3791\/55835.","journal-title":"J Vis Exp"},{"key":"7695_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/chem.202303921","volume":"30","author":"A Pees","year":"2024","unstructured":"Pees A, Tong J, Birudaraju S, Munot YS, Liang SH, Saturnino Guarino D, et al. Development of pyridothiophene compounds for PET imaging of \u03b1-synuclein. Chemistry. 2024;30:e202303921. https:\/\/doi.org\/10.1002\/chem.202303921.","journal-title":"Chemistry"},{"key":"7695_CR45","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s00401-020-02157-3","volume":"139","author":"A Van der Perren","year":"2020","unstructured":"Van der Perren A, Gelders G, Fenyi A, Bousset L, Brito F, Peelaerts W, et al. The structural differences between patient-derived \u03b1-synuclein strains dictate characteristics of parkinson\u2019s disease, multiple system atrophy and dementia with lewy bodies. Acta Neuropathol. 2020;139:977\u20131000. https:\/\/doi.org\/10.1007\/s00401-020-02157-3.","journal-title":"Acta Neuropathol"},{"key":"7695_CR46","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1007\/s11307-023-01814-9","volume":"25","author":"B Janssen","year":"2023","unstructured":"Janssen B, Tian G, Lengyel-Zhand Z, Hsieh C-J, Lougee MG, Riad A, et al. Identification of a putative \u03b1-synuclein radioligand using an in silico similarity search. Mol Imaging Biol. 2023;25:704\u201319. https:\/\/doi.org\/10.1007\/s11307-023-01814-9.","journal-title":"Mol Imaging Biol"},{"key":"7695_CR47","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1016\/j.neuron.2024.05.006","volume":"112","author":"H Endo","year":"2024","unstructured":"Endo H, Ono M, Takado Y, Matsuoka K, Takahashi M, Tagai K, et al. Imaging \u03b1-synuclein pathologies in animal models and patients with parkinson\u2019s and related diseases. Neuron. 2024;112:2540\u2013e578. https:\/\/doi.org\/10.1016\/j.neuron.2024.05.006.","journal-title":"Neuron"},{"key":"7695_CR48","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1021\/acschemneuro.4c00493","volume":"15","author":"D Saturnino Guarino","year":"2024","unstructured":"Saturnino Guarino D, Miranda Azpiazu P, Sunnemark D, Elmore CS, Bergare J, Artelsmair M, et al. Identification and in vitro and in vivo characterization of KAC-50.1 as a potential \u03b1-synuclein PET radioligand. ACS Chem Neurosci. 2024;15:4210\u20139. https:\/\/doi.org\/10.1021\/acschemneuro.4c00493.","journal-title":"ACS Chem Neurosci"},{"key":"7695_CR49","doi-asserted-by":"publisher","first-page":"6750","DOI":"10.1038\/s41467-023-42305-3","volume":"14","author":"R Smith","year":"2023","unstructured":"Smith R, Capotosti F, Schain M, Ohlsson T, Vokali E, Molette J, et al. The \u03b1-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases. Nat Commun. 2023;14:6750. https:\/\/doi.org\/10.1038\/s41467-023-42305-3.","journal-title":"Nat Commun"},{"key":"7695_CR50","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40478-021-01175-w","volume":"9","author":"C Bargar","year":"2021","unstructured":"Bargar C, Wang W, Gunzler SA, LeFevre A, Wang Z, Lerner AJ, et al. Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in parkinson\u2019s disease and dementia with lewy bodies. Acta Neuropathol Commun. 2021;9:62. https:\/\/doi.org\/10.1186\/s40478-021-01175-w.","journal-title":"Acta Neuropathol Commun"},{"key":"7695_CR51","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1126\/science.1131864","volume":"313","author":"M Meyer-Luehmann","year":"2006","unstructured":"Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, et al. Exogenous induction of cerebral b-Amyloidogenesis is governed by agent and host. Science. 2006;313:1781\u20134.","journal-title":"Science"},{"key":"7695_CR52","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/jnc.15713","volume":"164","author":"S Mukherjee","year":"2023","unstructured":"Mukherjee S, Dubois C, Perez K, Varghese S, Birchall IE, Leckey M, et al. Quantitative proteomics of tau and A\u03b2 in detergent fractions from Alzheimer\u2019s disease brains. J Neurochem. 2023;164:529\u201352. https:\/\/doi.org\/10.1111\/jnc.15713.","journal-title":"J Neurochem"},{"key":"7695_CR53","doi-asserted-by":"publisher","unstructured":"Rostagno A, Ghiso J. Isolation and biochemical characterization of amyloid plaques and paired helical filaments. Curr Protoc Cell Biol. 2009;Chap3\u2013Unit33331. https:\/\/doi.org\/10.1002\/0471143030.cb0333s44.","DOI":"10.1002\/0471143030.cb0333s44"},{"key":"7695_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-025-00469-6","volume":"14","author":"JA Wiseman","year":"2025","unstructured":"Wiseman JA, Turner CP, Faull RLM, Halliday GM, Dieriks BV. Refining alpha-synuclein seed amplification assays to distinguish Parkinson\u2019s disease from multiple system atrophy. Transl Neurodegener. 2025;14:7. https:\/\/doi.org\/10.1186\/s40035-025-00469-6.","journal-title":"Transl Neurodegener"},{"key":"7695_CR55","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1038\/nprot.2016.120","volume":"11","author":"M Schmitz","year":"2016","unstructured":"Schmitz M, Cramm M, Llorens F, Muller-Cramm D, Collins S, Atarashi R, et al. The real-time quaking-induced conversion assay for detection of human prion disease and study of other protein misfolding diseases. Nat Protoc. 2016;11:2233\u201342. https:\/\/doi.org\/10.1038\/nprot.2016.120.","journal-title":"Nat Protoc"},{"key":"7695_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1177556","volume":"10","author":"H Gram","year":"2023","unstructured":"Gram H, Theologidis V, Boesen T, Jensen PH. Sarkosyl differentially solubilizes patient-derived alpha-synuclein fibril strains. Front Mol Biosci. 2023;10:1177556. https:\/\/doi.org\/10.3389\/fmolb.2023.1177556.","journal-title":"Front Mol Biosci"},{"key":"7695_CR57","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00401-025-02853-y","volume":"149","author":"AM Bernhardt","year":"2025","unstructured":"Bernhardt AM, Longen S, Trossbach SV, Rossi M, Weckbecker D, Schmidt F, et al. A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for Parkinson\u2019s disease. Acta Neuropathol. 2025;149:20. https:\/\/doi.org\/10.1007\/s00401-025-02853-y.","journal-title":"Acta Neuropathol"},{"key":"7695_CR58","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nsmb.3194","volume":"23","author":"MD Tuttle","year":"2016","unstructured":"Tuttle MD, Comellas G, Nieuwkoop AJ, Covell DJ, Berthold DA, Kloepper KD, et al. Solid-state NMR structure of a pathogenic fibril of full-length human \u03b1-synuclein. Nat Struct Mol Biol. 2016;23:409\u201315. https:\/\/doi.org\/10.1038\/nsmb.3194.","journal-title":"Nat Struct Mol Biol"},{"key":"7695_CR59","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1134\/S0006297922050066","volume":"87","author":"AB Matiiv","year":"2022","unstructured":"Matiiv AB, Trubitsina NP, Matveenko AG, Barbitoff YA, Zhouravleva GA, Bondarev SA. Structure and polymorphism of amyloid and amyloid-like aggregates. Biochem (Moscow). 2022;87:450\u201363. https:\/\/doi.org\/10.1134\/S0006297922050066.","journal-title":"Biochem (Moscow)"},{"key":"7695_CR60","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1038\/s41467-018-05971-2","volume":"9","author":"B Li","year":"2018","unstructured":"Li B, Ge P, Murray KA, Sheth P, Zhang M, Nair G, et al. Cryo-EM of full-length \u03b1-synuclein reveals fibril polymorphs with a common structural kernel. Nat Commun. 2018;9:3609. https:\/\/doi.org\/10.1038\/s41467-018-05971-2.","journal-title":"Nat Commun"},{"key":"7695_CR61","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.36402","volume":"7","author":"R Guerrero-Ferreira","year":"2018","unstructured":"Guerrero-Ferreira R, Taylor NMI, Mona D, Ringler P, Lauer ME, Riek R, et al. Cryo-EM structure of alpha-synuclein fibrils. Elife. 2018;7:e36402. https:\/\/doi.org\/10.7554\/eLife.36402.","journal-title":"Elife"},{"key":"7695_CR62","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.48907","volume":"8","author":"R Guerrero-Ferreira","year":"2019","unstructured":"Guerrero-Ferreira R, Taylor NMI, Arteni A-A, Kumari P, Mona D, Ringler P, et al. Two new polymorphic structures of human full-length alpha-synuclein fibrils solved by cryo-electron microscopy. Elife. 2019;8:e48907. https:\/\/doi.org\/10.7554\/eLife.48907.","journal-title":"Elife"},{"key":"7695_CR63","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.str.2022.11.013","volume":"31","author":"Y Fan","year":"2023","unstructured":"Fan Y, Sun Y, Yu W, Tao Y, Xia W, Liu Y, et al. Conformational change of \u03b1-synuclein fibrils in cerebrospinal fluid from different clinical phases of Parkinson\u2019s disease. Structure. 2023;31:78-87.e5. https:\/\/doi.org\/10.1016\/j.str.2022.11.013.","journal-title":"Structure"},{"key":"7695_CR64","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00401-023-02550-8","volume":"145","author":"Y Yang","year":"2023","unstructured":"Yang Y, Garringer HJ, Shi Y, L\u00f6vestam S, Peak-Chew S, Zhang X, et al. New SNCA mutation and structures of \u03b1-synuclein filaments from juvenile-onset synucleinopathy. Acta Neuropathol. 2023;145:561\u201372. https:\/\/doi.org\/10.1007\/s00401-023-02550-8.","journal-title":"Acta Neuropathol"},{"key":"7695_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1254721","author":"L Gardon","year":"2023","unstructured":"Gardon L, Becker N, R\u00e4hse N, H\u00f6lbling C, Apostolidis A, Schulz CM, et al. Amyloid fibril formation kinetics of low-pH denatured bovine PI3K-SH3 monitored by three different NMR techniques. Front Mol Biosci. 2023. https:\/\/doi.org\/10.3389\/fmolb.2023.1254721.","journal-title":"Front Mol Biosci"},{"key":"7695_CR66","doi-asserted-by":"publisher","first-page":"5385","DOI":"10.1038\/s41467-022-32797-w","volume":"13","author":"L Antonschmidt","year":"2022","unstructured":"Antonschmidt L, Matthes D, Dervi\u015fo\u011flu R, Frieg B, Dienemann C, Leonov A, et al. The clinical drug candidate anle138b binds in a cavity of lipidic \u03b1-synuclein fibrils. Nat Commun. 2022;13:5385. https:\/\/doi.org\/10.1038\/s41467-022-32797-w.","journal-title":"Nat Commun"},{"key":"7695_CR67","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1002\/cbic.202000143","volume":"21","author":"Z Niu","year":"2020","unstructured":"Niu Z, Sarkar R, Aichler M, Wester HJ, Yousefi BH, Reif B. Mapping the binding interface of PET tracer molecules and alzheimer disease A\u03b2 fibrils by using MAS solid-state NMR spectroscopy. Chembiochem. 2020;21:2495\u2013502. https:\/\/doi.org\/10.1002\/cbic.202000143.","journal-title":"Chembiochem"},{"key":"7695_CR68","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1021\/acschemneuro.8b00177","volume":"9","author":"C-J Hsieh","year":"2018","unstructured":"Hsieh C-J, Ferrie JJ, Xu K, Lee I, Graham TJA, Tu Z, et al. Alpha synuclein fibrils contain multiple binding sites for small molecules. ACS Chem Neurosci. 2018;9:2521\u20137. https:\/\/doi.org\/10.1021\/acschemneuro.8b00177.","journal-title":"ACS Chem Neurosci"},{"key":"7695_CR69","doi-asserted-by":"publisher","first-page":"12746","DOI":"10.1039\/d0sc02159h","volume":"11","author":"JJ Ferrie","year":"2020","unstructured":"Ferrie JJ, Lengyel-Zhand Z, Janssen B, Lougee MG, Giannakoulias S, Hsieh CJ, et al. Identification of a nanomolar affinity \u03b1-synuclein fibril imaging probe by ultra-high throughput in silico screening. Chem Sci. 2020;11:12746\u201354. https:\/\/doi.org\/10.1039\/d0sc02159h.","journal-title":"Chem Sci"},{"key":"7695_CR70","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1038\/s41467-024-46832-5","volume":"15","author":"DD Dhavale","year":"2024","unstructured":"Dhavale DD, Barclay AM, Borcik CG, Basore K, Berthold DA, Gordon IR, et al. Structure of alpha-synuclein fibrils derived from human lewy body dementia tissue. Nat Commun. 2024;15:2750. https:\/\/doi.org\/10.1038\/s41467-024-46832-5.","journal-title":"Nat Commun"},{"key":"7695_CR71","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/j.neuron.2025.03.019","volume":"113","author":"Y Han","year":"2025","unstructured":"Han Y, Li J, Xia W, Li Q, Sun Z, Zeng W, et al. Fibril fuzzy coat is important for alpha-synuclein pathological transmission activity. Neuron. 2025;113:1723\u2013e407. https:\/\/doi.org\/10.1016\/j.neuron.2025.03.019.","journal-title":"Neuron"},{"key":"7695_CR72","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.pnmrs.2023.07.001","volume":"138\u2013139","author":"C Dalvit","year":"2023","unstructured":"Dalvit C, Gm\u00fcr I, R\u00f6\u00dfler P, Gossert AD. Affinity measurement of strong ligands with NMR spectroscopy: limitations and ways to overcome them. Prog Nucl Magn Reson Spectrosc. 2023;138\u2013139:52\u201369. https:\/\/doi.org\/10.1016\/j.pnmrs.2023.07.001.","journal-title":"Prog Nucl Magn Reson Spectrosc"},{"key":"7695_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.661117","author":"R Bell","year":"2021","unstructured":"Bell R, Vendruscolo M. Modulation of the interactions between \u03b1-synuclein and lipid membranes by post-translational modifications. Front Neurol. 2021. https:\/\/doi.org\/10.3389\/fneur.2021.661117.","journal-title":"Front Neurol"},{"key":"7695_CR74","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s12104-024-10186-2","volume":"18","author":"Z Toleikis","year":"2024","unstructured":"Toleikis Z, Paluch P, Kuc E, Petkus J, Sulskis D, Org-Tago M-L, et al. Solid-state NMR backbone chemical shift assignments of \u03b1-synuclein amyloid fibrils at fast MAS regime. Biomol NMR Assign. 2024;18:181\u20136. https:\/\/doi.org\/10.1007\/s12104-024-10186-2.","journal-title":"Biomol NMR Assign"},{"key":"7695_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2019.00033","author":"M Serna","year":"2019","unstructured":"Serna M. Hands on methods for high resolution cryo-electron microscopy structures of heterogeneous macromolecular complexes. Front Mol Biosci. 2019. https:\/\/doi.org\/10.3389\/fmolb.2019.00033.","journal-title":"Front Mol Biosci"},{"key":"7695_CR76","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-1-61779-909-9_3","volume-title":"Receptor binding techniques","author":"JJ Maguire","year":"2012","unstructured":"Maguire JJ, Kuc RE, Davenport AP. Radioligand binding assays and their analysis. In: Davenport AP, editor. Receptor binding techniques. Totowa, NJ: Humana; 2012. pp. 31\u201377."},{"key":"7695_CR77","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/978-1-4684-8619-3_48","volume-title":"Advances in tracer methodology: volume 1","author":"JH Taylor","year":"1963","unstructured":"Taylor JH. Some uses of tritium in autoradiography. In: Rothchild S, editor. Advances in tracer methodology: volume 1. Boston, MA: Springer US; 1963. pp. 295\u2013301."},{"key":"7695_CR78","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/BF01191605","volume":"3","author":"DF H\u00fclser","year":"1966","unstructured":"H\u00fclser DF, Rajewsky MF. Characteristics of three nuclear emulsions for autoradiography at the electron microscope. Biophysik. 1966;3:123\u201330. https:\/\/doi.org\/10.1007\/BF01191605.","journal-title":"Biophysik"},{"key":"7695_CR79","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.phpro.2015.11.082","volume":"80","author":"K Morishima","year":"2015","unstructured":"Morishima K. Latest developments in nuclear emulsion technology. Phys Procedia. 2015;80:19\u201324. https:\/\/doi.org\/10.1016\/j.phpro.2015.11.082.","journal-title":"Phys Procedia"},{"key":"7695_CR80","doi-asserted-by":"publisher","DOI":"10.3791\/58879","author":"N Griem-Krey","year":"2019","unstructured":"Griem-Krey N, Klein AB, Herth M, Wellendorph P. Autoradiography as a simple and powerful method for visualization and characterization of pharmacological targets. J Vis Exp. 2019. https:\/\/doi.org\/10.3791\/58879.","journal-title":"J Vis Exp"},{"key":"7695_CR81","volume-title":"Assay guidance manual","author":"DS Auld","year":"2004","unstructured":"Auld DS, Farmen MW, Kahl SD, Kriauciunas A, McKnight KL, Montrose C, et al. Receptor binding assays for HTS and drug discovery. In: Markossian S, Grossman A, Arkin M, Auld D, Austin C, Baell J, et al. editors. Assay guidance manual. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004."},{"key":"7695_CR82","doi-asserted-by":"publisher","first-page":"24774","DOI":"10.1021\/acsomega.4c01301","volume":"9","author":"F Bonanno","year":"2024","unstructured":"Bonanno F, Saw RS, Bleher D, Papadopoulos I, Bowden GD, Bjerregaard-Andersen K, et al. Advancing Parkinson\u2019s disease diagnostics: the potential of arylpyrazolethiazole derivatives for imaging \u03b1-Synuclein aggregates. ACS Omega. 2024;9:24774\u201388. https:\/\/doi.org\/10.1021\/acsomega.4c01301.","journal-title":"ACS Omega"},{"key":"7695_CR83","doi-asserted-by":"publisher","first-page":"31450","DOI":"10.1021\/acsomega.3c04292","volume":"8","author":"A Di Nanni","year":"2023","unstructured":"Di Nanni A, Saw RS, Battisti UM, Bowden GD, Boeckermann A, Bjerregaard-Andersen K, et al. A fluorescent probe as a lead compound for a selective \u03b1-Synuclein PET tracer: development of a library of 2-styrylbenzothiazoles and biological evaluation of [(18)F]PFSB and [(18)F]MFSB. ACS Omega. 2023;8:31450\u201367. https:\/\/doi.org\/10.1021\/acsomega.3c04292.","journal-title":"ACS Omega"},{"key":"7695_CR84","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/s41380-022-01875-2","volume":"28","author":"M-L Malarte","year":"2023","unstructured":"Malarte M-L, Gillberg P-G, Kumar A, Bogdanovic N, Lemoine L, Nordberg A. Discriminative binding of Tau PET tracers PI2620, MK6240 and RO948 in Alzheimer\u2019s disease, corticobasal degeneration and progressive supranuclear palsy brains. Mol Psychiatry. 2023;28:1272\u201383. https:\/\/doi.org\/10.1038\/s41380-022-01875-2.","journal-title":"Mol Psychiatry"},{"key":"7695_CR85","doi-asserted-by":"publisher","first-page":"12695","DOI":"10.1021\/acs.jmedchem.4c00686","volume":"67","author":"Q Zeng","year":"2024","unstructured":"Zeng Q, Zhang X, Li Y, Zhang Q, Dai J, Yan X-x, et al. Discovery and evaluation of imidazo[2,1-b][1,3,4]thiadiazole derivatives as new candidates for \u03b1-Synuclein PET imaging. J Med Chem. 2024;67:12695\u2013710. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c00686.","journal-title":"J Med Chem"},{"key":"7695_CR86","unstructured":"Grasso, L. Micro-radiobinding assays for ligand screening. WO2021\/064610 A1. 2021."},{"key":"7695_CR87","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00441-014-2093-4","volume":"360","author":"EG Solon","year":"2015","unstructured":"Solon EG. Autoradiography techniques and quantification of drug distribution. Cell Tissue Res. 2015;360:87\u2013107. https:\/\/doi.org\/10.1007\/s00441-014-2093-4.","journal-title":"Cell Tissue Res"},{"key":"7695_CR88","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/978-1-61779-909-9_10","volume-title":"Receptor binding techniques","author":"P Johnstr\u00f6m","year":"2012","unstructured":"Johnstr\u00f6m P, Bird JL, Davenport AP. Quantitative phosphor imaging autoradiography of radioligands for positron emission tomography. In: Davenport AP, editor. Receptor binding techniques. Totowa, NJ: Humana; 2012. pp. 205\u201320."},{"key":"7695_CR89","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1210\/endo-39-1-8","volume":"39","author":"LF Belanger","year":"1946","unstructured":"Belanger LF, Leblond CP. A method for locating radioactive elements in tissues by covering histological sections with a photographic emulsion. Endocrinology. 1946;39:8\u201313. https:\/\/doi.org\/10.1210\/endo-39-1-8.","journal-title":"Endocrinology"},{"key":"7695_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-021-00273-9","volume":"8","author":"K Men\u0161\u00edkov\u00e1","year":"2022","unstructured":"Men\u0161\u00edkov\u00e1 K, Mat\u011bj R, Colosimo C, Rosales R, Tu\u010dkov\u00e1 L, Ehrmann J, et al. Lewy body disease or diseases with Lewy bodies? npj Parkinson\u2019s Disease. 2022;8:3. https:\/\/doi.org\/10.1038\/s41531-021-00273-9.","journal-title":"npj Parkinson's Disease"},{"key":"7695_CR91","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/10408347.2014.881250","volume":"45","author":"A Olaru","year":"2015","unstructured":"Olaru A, Bala C, Jaffrezic-Renault N, Aboul-Enein HY. Surface Plasmon Resonance (SPR) Biosensors in Pharmaceutical Analysis. Crit Rev Anal Chem. 2015;45:97\u2013105. https:\/\/doi.org\/10.1080\/10408347.2014.881250.","journal-title":"Crit Rev Anal Chem"},{"key":"7695_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2022.105422","volume":"161","author":"M Sevenich","year":"2022","unstructured":"Sevenich M, Honold D, Willuweit A, Kutzsche J, Mohrl\u00fcder J, Willbold D. Development of an \u03b1-synuclein fibril and oligomer specific tracer for diagnosis of Parkinson\u2019s disease, dementia with Lewy bodies and multiple system atrophy. Neurochem Int. 2022;161:105422. https:\/\/doi.org\/10.1016\/j.neuint.2022.105422.","journal-title":"Neurochem Int"},{"key":"7695_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2020.115358","volume":"28","author":"YF Chen","year":"2020","unstructured":"Chen YF, Bian J, Zhang P, Bu LL, Shen Y, Yu WB, et al. Design, synthesis and identification of N, N-dibenzylcinnamamide (DBC) derivatives as novel ligands for \u03b1-synuclein fibrils by SPR evaluation system. Bioorg Med Chem. 2020;28:115358. https:\/\/doi.org\/10.1016\/j.bmc.2020.115358.","journal-title":"Bioorg Med Chem"},{"key":"7695_CR94","unstructured":"Wang C, Gomperts SN, Bai P, Bartels T, Khurana V. Modulators of Neurodegeneration. In: Organization WO2025\/019589 A2. 2025."},{"key":"7695_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.trac.2024.117741","volume":"176","author":"A Jug","year":"2024","unstructured":"Jug A, Bratkovi\u010d T, Ila\u0161 J. Biolayer interferometry and its applications in drug discovery and development. TrAC Trends Anal Chem. 2024;176:117741. https:\/\/doi.org\/10.1016\/j.trac.2024.117741.","journal-title":"TrAC Trends Anal Chem"},{"key":"7695_CR96","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3762\/bjnano.6.12","volume":"6","author":"S Povilonien\u0117","year":"2015","unstructured":"Povilonien\u0117 S, \u010casait\u0117 V, Bukauskas V, \u0160etkus A, Staniulis J, Me\u0161kys R. Functionalization of \u03b1-synuclein fibrils. Beilstein J Nanotechnol. 2015;6:124\u201333. https:\/\/doi.org\/10.3762\/bjnano.6.12.","journal-title":"Beilstein J Nanotechnol"},{"key":"7695_CR97","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/jlcr.4019","volume":"66","author":"A Lindberg","year":"2023","unstructured":"Lindberg A, Chasse M, Varlow C, Pees A, Vasdev N. Strategies for designing novel positron emission tomography (PET) radiotracers to cross the blood-brain barrier. J Labelled Comp Radiopharm. 2023;66:205\u201321. https:\/\/doi.org\/10.1002\/jlcr.4019.","journal-title":"J Labelled Comp Radiopharm"},{"issue":"19","key":"7695_CR98","doi-asserted-by":"publisher","DOI":"10.3390\/cells14191531","volume":"14","author":"C Zheng","year":"2025","unstructured":"Zheng C, Stehouwer J, Ummenthala GR, Munot Y, Vasdev N. Multi-Fused S,N-Heterocyclic Compounds for Targeting \u03b1-Synuclein Aggregates. Cells. 2025;14(19):1531. https:\/\/doi.org\/10.3390\/cells14191531.","journal-title":"Cells"},{"key":"7695_CR99","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1602\/neurorx.2.4.541","volume":"2","author":"H Pajouhesh","year":"2005","unstructured":"Pajouhesh H, Lenz GR. Medicinal chemical properties of successful central nervous system drugs. NeuroRx. 2005;2:541\u201353. https:\/\/doi.org\/10.1602\/neurorx.2.4.541.","journal-title":"NeuroRx"},{"key":"7695_CR100","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21218182","author":"M Ooka","year":"2020","unstructured":"Ooka M, Lynch C, Xia M. Application of in vitro metabolism activation in high-throughput screening. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21218182.","journal-title":"Int J Mol Sci"},{"key":"7695_CR101","doi-asserted-by":"crossref","unstructured":"Jan\u010dov\u00e1 P, \u0160iller M. Phase II drug metabolism. In: Paxton J, editor. Topics on drug metabolism. Rijeka: IntechOpen; 2012, ch. 2.","DOI":"10.5772\/29996"},{"key":"7695_CR102","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1007\/s00259-020-05133-x","volume":"48","author":"L Kuebler","year":"2021","unstructured":"Kuebler L, Buss S, Leonov A, Ryazanov S, Schmidt F, Maurer A, et al. [(11)C]MODAG-001-towards a PET tracer targeting alpha-synuclein aggregates. Eur J Nucl Med Mol Imaging. 2021;48:1759\u201372. https:\/\/doi.org\/10.1007\/s00259-020-05133-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7695_CR103","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jchromb.2017.07.003","volume":"1061\u20131062","author":"X Zhang","year":"2017","unstructured":"Zhang X, Yin J, Liang C, Sun Y, Zhang L. A simple and sensitive UHPLC\u2013Q\u2013TOF\u2013MS\/MS method for sophoricoside metabolism study in vitro and in vivo. J Chromatogr B. 2017;1061\u20131062:193\u2013208. https:\/\/doi.org\/10.1016\/j.jchromb.2017.07.003.","journal-title":"J Chromatogr B"},{"key":"7695_CR104","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.addr.2015.03.011","volume":"86","author":"G Lambrinidis","year":"2015","unstructured":"Lambrinidis G, Vallianatou T, Tsantili-Kakoulidou A. In vitro, in silico and integrated strategies for the estimation of plasma protein binding. A review. Adv Drug Deliv Rev. 2015;86:27\u201345. https:\/\/doi.org\/10.1016\/j.addr.2015.03.011.","journal-title":"Adv Drug Deliv Rev"},{"key":"7695_CR105","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.1021\/jm400312y","volume":"56","author":"L Zhang","year":"2013","unstructured":"Zhang L, Villalobos A, Beck EM, Bocan T, Chappie TA, Chen L, et al. Design and selection parameters to accelerate the discovery of novel central nervous system positron emission tomography (PET) ligands and their application in the development of a novel phosphodiesterase 2A PET ligand. J Med Chem. 2013;56:4568\u201379. https:\/\/doi.org\/10.1021\/jm400312y.","journal-title":"J Med Chem"},{"key":"7695_CR106","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032710","volume":"24","author":"B Chaulagain","year":"2023","unstructured":"Chaulagain B, Gothwal A, Lamptey RNL, Trivedi R, Mahanta AK, Layek B, et al. Experimental models of in vitro blood\u2013brain barrier for CNS drug delivery: an evolutionary perspective. Int J Mol Sci. 2023;24:2710.","journal-title":"Int J Mol Sci"},{"key":"7695_CR107","volume-title":"Bench to bedside","author":"Central Nervous System Radiotracer Development","year":"2024","unstructured":"Central Nervous System Radiotracer Development. Bench to bedside. Vienna: INTERNATIONAL ATOMIC ENERGY AGENCY; 2024."},{"key":"7695_CR108","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202201401","volume":"18","author":"S Kawakita","year":"2022","unstructured":"Kawakita S, Mandal K, Mou L, Mecwan MM, Zhu Y, Li S, et al. Organ\u2010on\u2010a\u2010chip models of the blood\u2013brain barrier: recent advances and future prospects. Small. 2022;18:e2201401. https:\/\/doi.org\/10.1002\/smll.202201401.","journal-title":"Small"},{"key":"7695_CR109","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.tips.2009.05.005","volume":"30","author":"VW Pike","year":"2009","unstructured":"Pike VW. PET radiotracers: crossing the blood\u2013brain barrier and surviving metabolism. Trends Pharmacol Sci. 2009;30:431\u201340. https:\/\/doi.org\/10.1016\/j.tips.2009.05.005.","journal-title":"Trends Pharmacol Sci"},{"key":"7695_CR110","volume-title":"Volume of Distribution. StatPearls","author":"A Mansoor","year":"2025","unstructured":"Mansoor A, Mahabadi N. Volume of Distribution. StatPearls. Treasure Island (FL): StatPearls Publishing; 2025."},{"key":"7695_CR111","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s00259-022-05997-1","volume":"50","author":"WJ Harris","year":"2023","unstructured":"Harris WJ, Asselin MC, Hinz R, Parkes LM, Allan S, Schiessl I, et al. In vivo methods for imaging blood-brain barrier function and dysfunction. Eur J Nucl Med Mol Imaging. 2023;50:1051\u201383. https:\/\/doi.org\/10.1007\/s00259-022-05997-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7695_CR112","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1097\/00004647-199609000-00008","volume":"16","author":"J Logan","year":"1996","unstructured":"Logan J, Fowler JS, Volkow ND, Wang G-J, Ding Y-S, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834\u201340. https:\/\/doi.org\/10.1097\/00004647-199609000-00008.","journal-title":"J Cereb Blood Flow Metab"},{"key":"7695_CR113","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.tips.2009.05.005","volume":"30","author":"VW Pike","year":"2009","unstructured":"Pike VW. PET radiotracers: crossing the blood-brain barrier and surviving metabolism. Trends Pharmacol Sci. 2009;30:431\u201340. https:\/\/doi.org\/10.1016\/j.tips.2009.05.005.","journal-title":"Trends Pharmacol Sci"},{"key":"7695_CR114","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-020-00692-4","volume":"10","author":"KK Ghosh","year":"2020","unstructured":"Ghosh KK, Padmanabhan P, Yang CT, Mishra S, Halldin C, Guly\u00e1s B. Dealing with PET radiometabolites. EJNMMI Res. 2020;10:109. https:\/\/doi.org\/10.1186\/s13550-020-00692-4.","journal-title":"EJNMMI Res"},{"key":"7695_CR115","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10102447","author":"W Ban","year":"2022","unstructured":"Ban W, You Y, Yang Z. Imaging technologies for cerebral pharmacokinetic studies: progress and perspectives. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10102447.","journal-title":"Biomedicines"},{"key":"7695_CR116","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.bja.2020.08.052","volume":"126","author":"K Varn\u00e4s","year":"2021","unstructured":"Varn\u00e4s K, Finnema SJ, Johnstr\u00f6m P, Arakawa R, Halldin C, Eriksson LI, et al. Effects of sevoflurane anaesthesia on radioligand binding to monoamine oxidase-B in vivo. Br J Anaesth. 2021;126:238\u201344. https:\/\/doi.org\/10.1016\/j.bja.2020.08.052.","journal-title":"Br J Anaesth"},{"key":"7695_CR117","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1023\/A:1015874329265","volume":"7","author":"H Cheng","year":"1990","unstructured":"Cheng H, Jusko WJ. Constant-rate intravenous infusion methods for estimating steady-state volumes of distribution and mean residence times in the body for drugs undergoing reversible metabolism. Pharm Res. 1990;7:628\u201332. https:\/\/doi.org\/10.1023\/A:1015874329265.","journal-title":"Pharm Res"},{"key":"7695_CR118","doi-asserted-by":"publisher","first-page":"e0158798","DOI":"10.1371\/journal.pone.0158798","volume":"11","author":"CA Wesolowski","year":"2016","unstructured":"Wesolowski CA, Wesolowski MJ, Babyn PS, Wanasundara SN. Time varying apparent volume of distribution and drug half-lives following intravenous bolus injections. PLoS One. 2016;11:e0158798. https:\/\/doi.org\/10.1371\/journal.pone.0158798.","journal-title":"PLoS One"},{"key":"7695_CR119","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/j.1365-2885.2004.00602.x","volume":"27","author":"PL Toutain","year":"2004","unstructured":"Toutain PL, Bousquet-M\u00e9lou A. Volumes of distribution. J Vet Pharmacol Ther. 2004;27:441\u201353. https:\/\/doi.org\/10.1111\/j.1365-2885.2004.00602.x.","journal-title":"J Vet Pharmacol Ther"},{"key":"7695_CR120","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/nrn.2017.75","volume":"18","author":"JB Koprich","year":"2017","unstructured":"Koprich JB, Kalia LV, Brotchie JM. Animal models of \u03b1-synucleinopathy for Parkinson disease drug development. Nat Rev Neurosci. 2017;18:515\u201329. https:\/\/doi.org\/10.1038\/nrn.2017.75.","journal-title":"Nat Rev Neurosci"},{"key":"7695_CR121","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1084\/jem.20112457","volume":"209","author":"KC Luk","year":"2012","unstructured":"Luk KC, Kehm VM, Zhang B, O\u2019Brien P, Trojanowski JQ, Lee VMY. Intracerebral inoculation of pathological \u03b1-synuclein initiates a rapidly progressive neurodegenerative \u03b1-synucleinopathy in mice. J Exp Med. 2012;209:975\u201386. https:\/\/doi.org\/10.1084\/jem.20112457.","journal-title":"J Exp Med"},{"key":"7695_CR122","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/s41598-022-04780-4","volume":"12","author":"S Awa","year":"2022","unstructured":"Awa S, Suzuki G, Masuda-Suzukake M, Nonaka T, Saito M, Hasegawa M. Phosphorylation of endogenous \u03b1-synuclein induced by extracellular seeds initiates at the pre-synaptic region and spreads to the cell body. Sci Rep. 2022;12:1163. https:\/\/doi.org\/10.1038\/s41598-022-04780-4.","journal-title":"Sci Rep"},{"key":"7695_CR123","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13024-021-00501-z","volume":"16","author":"S Koga","year":"2021","unstructured":"Koga S, Sekiya H, Kondru N, Ross OA, Dickson DW. Neuropathology and molecular diagnosis of synucleinopathies. Mol Neurodegener. 2021;16:83. https:\/\/doi.org\/10.1186\/s13024-021-00501-z.","journal-title":"Mol Neurodegener"},{"key":"7695_CR124","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s40478-022-01410-y","volume":"10","author":"S Lam","year":"2022","unstructured":"Lam S, H\u00e9rard A-S, Boluda S, Petit F, Eddarkaoui S, Cambon K, et al. Pathological changes induced by Alzheimer\u2019s brain inoculation in amyloid-beta plaque-bearing mice. Acta Neuropathol Commun. 2022;10:112. https:\/\/doi.org\/10.1186\/s40478-022-01410-y.","journal-title":"Acta Neuropathol Commun"},{"key":"7695_CR125","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1523\/JNEUROSCI.2642-12.2013","volume":"33","author":"M Iba","year":"2013","unstructured":"Iba M, Guo JL, McBride JD, Zhang B, Trojanowski JQ, Lee VMY. Synthetic Tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer\u2019s-like tauopathy. J Neurosci. 2013;33:1024. https:\/\/doi.org\/10.1523\/JNEUROSCI.2642-12.2013.","journal-title":"J Neurosci"},{"key":"7695_CR126","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1038\/s41593-023-01484-4","volume":"26","author":"M Zielinski","year":"2023","unstructured":"Zielinski M, Peralta Reyes FS, Gremer L, Schemmert S, Frieg B, Sch\u00e4fer LU, et al. Cryo-EM of A\u03b2 fibrils from mouse models find tg-APPArcSwe fibrils resemble those found in patients with sporadic Alzheimer\u2019s disease. Nat Neurosci. 2023;26:2073\u201380. https:\/\/doi.org\/10.1038\/s41593-023-01484-4.","journal-title":"Nat Neurosci"},{"key":"7695_CR127","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-023-00368-8","volume":"12","author":"A Dovonou","year":"2023","unstructured":"Dovonou A, Bolduc C, Soto Linan V, Gora C, Peralta MR Iii, L\u00e9vesque M. Animal models of Parkinson\u2019s disease: bridging the gap between disease hallmarks and research questions. Transl Neurodegener. 2023;12:36. https:\/\/doi.org\/10.1186\/s40035-023-00368-8.","journal-title":"Transl Neurodegener"},{"key":"7695_CR128","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.nbd.2004.07.001","volume":"17","author":"P-O Fernagut","year":"2004","unstructured":"Fernagut P-O, Chesselet M-F. Alpha-synuclein and transgenic mouse models. Neurobiol Dis. 2004;17:123\u201330. https:\/\/doi.org\/10.1016\/j.nbd.2004.07.001.","journal-title":"Neurobiol Dis"},{"key":"7695_CR129","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a023572","author":"R Riek","year":"2017","unstructured":"Riek R. The three-dimensional structures of amyloids. Cold Spring Harb Perspect Biol. 2017. https:\/\/doi.org\/10.1101\/cshperspect.a023572.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"7695_CR130","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3233\/jpd-230154","volume":"14","author":"L Walker","year":"2024","unstructured":"Walker L, Attems J. Prevalence of concomitant pathologies in Parkinson\u2019s disease: implications for prognosis, diagnosis, and insights into common pathogenic mechanisms. J Parkinson\u2019s Disease. 2024;14:35\u201352. https:\/\/doi.org\/10.3233\/jpd-230154.","journal-title":"J Parkinson\u2019s Disease"},{"key":"7695_CR131","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/S1474-4422(24)00402-2","volume":"23","author":"G May\u00e0","year":"2024","unstructured":"May\u00e0 G, Iranzo A, Gaig C, S\u00e1nchez-Valle R, Serradell M, Molina-Porcel L, et al. Post-mortem neuropathology of idiopathic rapid eye movement sleep behaviour disorder: a case series. Lancet Neurol. 2024;23:1238\u201351. https:\/\/doi.org\/10.1016\/S1474-4422(24)00402-2.","journal-title":"Lancet Neurol"},{"key":"7695_CR132","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s00259-019-04305-8","volume":"46","author":"NA Murugan","year":"2019","unstructured":"Murugan NA, Chiotis K, Rodriguez-Vieitez E, Lemoine L, \u00c5gren H, Nordberg A. Cross-interaction of Tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging. Eur J Nucl Med Mol Imaging. 2019;46:1369\u201382. https:\/\/doi.org\/10.1007\/s00259-019-04305-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7695_CR133","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/ggi.14729","volume":"24","author":"K Ishibashi","year":"2024","unstructured":"Ishibashi K. Clinical application of MAO-B PET using F-THK5351 in neurological disorders. Geriatr Gerontol Int. 2024;24:31\u201343. https:\/\/doi.org\/10.1111\/ggi.14729.","journal-title":"Geriatr Gerontol Int"},{"key":"7695_CR134","doi-asserted-by":"publisher","DOI":"10.3390\/ph14020110","author":"C Jie","year":"2021","unstructured":"Jie C, Treyer V, Schibli R, Mu L. Tauvid\u2122: the first FDA-approved PET tracer for imaging tau pathology in Alzheimer\u2019s disease. Pharmaceuticals (Basel). 2021. https:\/\/doi.org\/10.3390\/ph14020110.","journal-title":"Pharmaceuticals (Basel)"},{"key":"7695_CR135","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.2174\/156802612805219950","volume":"12","author":"M Naoi","year":"2012","unstructured":"Naoi M, Maruyama W, Inaba-Hasegawa K. Type A and B monoamine oxidase in age-related neurodegenerative disorders: their distinct roles in neuronal death and survival. Curr Top Med Chem. 2012;12:2177\u201388. https:\/\/doi.org\/10.2174\/156802612805219950.","journal-title":"Curr Top Med Chem"},{"key":"7695_CR136","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26123724","author":"T Behl","year":"2021","unstructured":"Behl T, Kaur D, Sehgal A, Singh S, Sharma N, Zengin G, et al. Role of monoamine oxidase activity in Alzheimer\u2019s disease: an insight into the therapeutic potential of inhibitors. Molecules. 2021. https:\/\/doi.org\/10.3390\/molecules26123724.","journal-title":"Molecules"},{"key":"7695_CR137","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.pnpbp.2012.06.001","volume":"39","author":"DI Brierley","year":"2012","unstructured":"Brierley DI, Davidson C. Developments in harmine pharmacology \u2014 implications for ayahuasca use and drug-dependence treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39:263\u201372. https:\/\/doi.org\/10.1016\/j.pnpbp.2012.06.001.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"7695_CR138","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1007\/s00259-019-04397-2","volume":"46","author":"H Kroth","year":"2019","unstructured":"Kroth H, Oden F, Molette J, Schieferstein H, Capotosti F, Mueller A, et al. Discovery and preclinical characterization of [18F]PI-2620, a next-generation Tau PET tracer for the assessment of Tau pathology in Alzheimer\u2019s disease and other Tauopathies. Eur J Nucl Med Mol Imaging. 2019;46:2178\u201389. https:\/\/doi.org\/10.1007\/s00259-019-04397-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7695_CR139","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1093\/brain\/aww098","volume":"139","author":"AK Hansen","year":"2016","unstructured":"Hansen AK, Knudsen K, Lillethorup TP, Landau AM, Parbo P, Fedorova T, et al. In vivo imaging of neuromelanin in Parkinson\u2019s disease using 18 F-AV-1451 PET. Brain. 2016;139:2039\u201349. https:\/\/doi.org\/10.1093\/brain\/aww098.","journal-title":"Brain"},{"key":"7695_CR140","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","volume":"24","author":"A Leuzy","year":"2019","unstructured":"Leuzy A, Chiotis K, Lemoine L, Gillberg P-G, Almkvist O, Rodriguez-Vieitez E, et al. Tau PET imaging in neurodegenerative tauopathies\u2014still a challenge. Mol Psychiatry. 2019;24:1112\u201334. https:\/\/doi.org\/10.1038\/s41380-018-0342-8.","journal-title":"Mol Psychiatry"},{"key":"7695_CR141","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/iub.2654","volume":"75","author":"FA Zucca","year":"2023","unstructured":"Zucca FA, Capucciati A, Bellei C, Sarna M, Sarna T, Monzani E, et al. Neuromelanins in brain aging and Parkinson\u2019s disease: synthesis, structure, neuroinflammatory, and neurodegenerative role. IUBMB Life. 2023;75:55\u201365. https:\/\/doi.org\/10.1002\/iub.2654.","journal-title":"IUBMB Life"},{"key":"7695_CR142","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07199-x","author":"A Kling","year":"2025","unstructured":"Kling A, Kusche-Palenga J, Palleis C, J\u00e4ck A, Bernhardt AM, Frontzkowski L, et al. Exploring the origins of frequent tau-PET signal in vermal and adjacent regions. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07199-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7695_CR143","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2024.108986","volume":"142\u2013143","author":"Y Yokoyama","year":"2025","unstructured":"Yokoyama Y, Harada R, Kudo K, Iwata R, Kudo Y, Okamura N, et al. Transmembrane protein 106B amyloid is a potential off-target molecule of tau PET tracers in the choroid plexus. Nucl Med Biol. 2025;142\u2013143:108986. https:\/\/doi.org\/10.1016\/j.nucmedbio.2024.108986.","journal-title":"Nucl Med Biol"},{"key":"7695_CR144","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28145359","author":"GM Nitulescu","year":"2023","unstructured":"Nitulescu GM, Stancov G, Seremet OC, Nitulescu G, Mihai DP, Duta-Bratu CG, et al. The importance of the pyrazole scaffold in the design of protein kinases inhibitors as targeted anticancer therapies. Molecules. 2023. https:\/\/doi.org\/10.3390\/molecules28145359.","journal-title":"Molecules"},{"key":"7695_CR145","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2020.00242","author":"CL Benn","year":"2020","unstructured":"Benn CL, Dawson LA. Clinically precedented protein kinases: rationale for their use in neurodegenerative disease. Front Aging Neurosci. 2020. https:\/\/doi.org\/10.3389\/fnagi.2020.00242.","journal-title":"Front Aging Neurosci"},{"key":"7695_CR146","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1021\/jm00081a001","volume":"35","author":"KA Jacobson","year":"1992","unstructured":"Jacobson KA, van Galen PJ, Williams M. Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential. J Med Chem. 1992;35:407\u201322. https:\/\/doi.org\/10.1021\/jm00081a001.","journal-title":"J Med Chem"},{"key":"7695_CR147","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.830704","volume":"14","author":"BC Uzuegbunam","year":"2022","unstructured":"Uzuegbunam BC, Li J, Paslawski W, Weber W, Svenningsson P, \u00c5gren H, et al. Toward novel [18F]fluorine-labeled radiotracers for the imaging of \u03b1-synuclein fibrils. Front Aging Neurosci. 2022;14:830704. https:\/\/doi.org\/10.3389\/fnagi.2022.830704.","journal-title":"Front Aging Neurosci"},{"key":"7695_CR148","doi-asserted-by":"publisher","first-page":"14470","DOI":"10.3390\/molecules181214470","volume":"18","author":"J Liu","year":"2013","unstructured":"Liu J, Sridhar J, Foroozesh M. Cytochrome P450 family 1 inhibitors and structure-activity relationships. Molecules. 2013;18:14470\u201395. https:\/\/doi.org\/10.3390\/molecules181214470.","journal-title":"Molecules"},{"key":"7695_CR149","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40478-017-0482-0","volume":"5","author":"M Marqui\u00e9","year":"2017","unstructured":"Marqui\u00e9 M, Verwer EE, Meltzer AC, Kim SJW, Ag\u00fcero C, Gonzalez J, et al. Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed parkinson\u2019s case. Acta Neuropathol Commun. 2017;5:75. https:\/\/doi.org\/10.1186\/s40478-017-0482-0.","journal-title":"Acta Neuropathol Commun"},{"key":"7695_CR150","doi-asserted-by":"publisher","first-page":"153601211879629","DOI":"10.1177\/1536012118796297","volume":"17","author":"L Josephson","year":"2018","unstructured":"Josephson L, Stratman N, Liu Y, Qian F, Liang SH, Vasdev N, et al. The binding of BF-227-Like Benzoxazoles to human alpha-Synuclein and amyloid beta peptide fibrils. Mol Imaging. 2018;17:1536012118796297. https:\/\/doi.org\/10.1177\/1536012118796297.","journal-title":"Mol Imaging"},{"key":"7695_CR151","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-024-00708-z","volume":"10","author":"M Matarazzo","year":"2024","unstructured":"Matarazzo M, Perez-Soriano A, Vafai N, Shahinfard E, Cheng KJ, McKenzie J, et al. Misfolded protein deposits in Parkinson\u2019s disease and Parkinson\u2019s disease-related cognitive impairment, a [(11)C]PBB3 study. NPJ Parkinsons Dis. 2024;10:96. https:\/\/doi.org\/10.1038\/s41531-024-00708-z.","journal-title":"NPJ Parkinsons Dis"},{"key":"7695_CR152","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.108985","volume":"208","author":"S Roshanbin","year":"2022","unstructured":"Roshanbin S, Xiong M, Hultqvist G, Soderberg L, Zachrisson O, Meier S, et al. In vivo imaging of alpha-synuclein with antibody-based PET. Neuropharmacology. 2022;208:108985. https:\/\/doi.org\/10.1016\/j.neuropharm.2022.108985.","journal-title":"Neuropharmacology"},{"key":"7695_CR153","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2024.108969","volume":"140","author":"TE Wuensche","year":"2025","unstructured":"Wuensche TE, Pereira PM, Windhorst AD, Bjerregaard-Andersen K, Sotty F, Kallunki P, et al. New prospects for (89)Zr-immuno-PET in brain applications - Alpha-synucleinopathies. Nucl Med Biol. 2025;140:108969. https:\/\/doi.org\/10.1016\/j.nucmedbio.2024.108969.","journal-title":"Nucl Med Biol"},{"key":"7695_CR154","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1002\/mds.29186","volume":"37","author":"K Matsuoka","year":"2022","unstructured":"Matsuoka K, Ono M, Takado Y, Hirata K, Endo H, Ohfusa T, et al. High-Contrast imaging of alpha-Synuclein pathologies in living patients with multiple system atrophy. Mov Disord. 2022;37:2159\u201361. https:\/\/doi.org\/10.1002\/mds.29186.","journal-title":"Mov Disord"},{"key":"7695_CR155","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-64540-6","volume":"16","author":"E Vokali","year":"2025","unstructured":"Vokali E, Chevalier E, Dreyfus N, Charmey D, Melly T, Kocher J, et al. Development of [(18)F]ACI-19626 as a first-in-class brain PET tracer for imaging TDP-43 pathology. Nat Commun. 2025;16:9358. https:\/\/doi.org\/10.1038\/s41467-025-64540-6.","journal-title":"Nat Commun"},{"key":"7695_CR156","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2020.147131","volume":"1749","author":"P Miranda-Azpiazu","year":"2020","unstructured":"Miranda-Azpiazu P, Svedberg M, Higuchi M, Ono M, Jia Z, Sunnemark D, et al. Identification and in vitro characterization of C05-01, a PBB3 derivative with improved affinity for alpha-synuclein. Brain Res. 2020;1749:147131. https:\/\/doi.org\/10.1016\/j.brainres.2020.147131.","journal-title":"Brain Res"},{"key":"7695_CR157","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.1007\/s00259-022-05898-3","volume":"49","author":"T Kimura","year":"2022","unstructured":"Kimura T, Ono M, Seki C, Sampei K, Shimojo M, Kawamura K, et al. A quantitative in vivo imaging platform for tracking pathological tau depositions and resultant neuronal death in a mouse model. Eur J Nucl Med Mol Imaging. 2022;49:4298\u2013311. https:\/\/doi.org\/10.1007\/s00259-022-05898-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7695_CR158","doi-asserted-by":"publisher","first-page":"8640","DOI":"10.1038\/s41598-025-93520-5","volume":"15","author":"R Goto","year":"2025","unstructured":"Goto R, Matsuoka K, Kimura Y, Kataoka Y, Oya M, Hirata K, et al. Human biodistribution and radiation dosimetry of two novel alpha-synuclein PET tracers, (18)F-SPAL-T-06 and (18)F-C05-05. Sci Rep. 2025;15:8640. https:\/\/doi.org\/10.1038\/s41598-025-93520-5.","journal-title":"Sci Rep"},{"key":"7695_CR159","unstructured":"Higuchi M, Ono M, Cho M, Yamamoto T, Wakabayashi K. Novel compound, alpha-synuclein aggregate binder, and use thereof. WO2022\/045093 A1. 2022."},{"key":"7695_CR160","volume-title":"Technology NIfQSa, Eisei R&D management Co. L","author":"M Higuchi","year":"2023","unstructured":"Higuchi M, Ono M, Cho M, Takado Y, Matsuoka K, Mizuma H, et al. Novel compound, \u03b1-synuclein aggregate binder, and use thereof. In: Technology NIfQSa, Eisei R&D management Co. L. editors. Japan: Ono Pharmaceutical Co. L, Ltd. TPC; 2023."},{"key":"7695_CR161","doi-asserted-by":"publisher","first-page":"9824","DOI":"10.1021\/acs.jmedchem.9b01220","volume":"62","author":"M Gupta","year":"2019","unstructured":"Gupta M, Lee HJ, Barden CJ, Weaver DF. The blood-brain barrier (BBB) score. J Med Chem. 2019;62:9824\u201336. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01220.","journal-title":"J Med Chem"},{"key":"7695_CR162","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1021\/cn100008c","volume":"1","author":"TT Wager","year":"2010","unstructured":"Wager TT, Hou X, Verhoest PR, Villalobos A. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chem Neurosci. 2010;1:435\u201349. https:\/\/doi.org\/10.1021\/cn100008c.","journal-title":"ACS Chem Neurosci"},{"key":"7695_CR163","unstructured":"Li D, Bian J, Liu C, Tan L, Zhang S, Han C. Compound for recognizing alpha-synuclein aggregate, and use thereof. WO2025\/162452. 2025."},{"key":"7695_CR164","unstructured":"Borroni E, Gobbi L, Honer M, Edelmann M, Mitchell D, Hardick D et al. Radiolabeled Compd. WO2019\/121661 A1. 2019."},{"key":"7695_CR165","doi-asserted-by":"publisher","DOI":"10.3390\/cells14151157","author":"C-J Hsieh","year":"2025","unstructured":"Hsieh C-J, Saturnino Guarino D, Young AJ, Siderowf AD, Nasrallah I, Schmitz A, et al. Pilot study of [11C]HY-2-15: a mixed alpha-synuclein and tau PET radiotracer. Cells. 2025. https:\/\/doi.org\/10.3390\/cells14151157.","journal-title":"Cells"},{"key":"7695_CR166","doi-asserted-by":"publisher","DOI":"10.1039\/d5md00057b","author":"GL Tian","year":"2025","unstructured":"Tian GL, Hsieh CJ, Guarino DS, Graham TJA, Lengyel-Zhand Z, Schmitz A, et al. The development of a PET radiotracer for imaging alpha synuclein aggregates in Parkinson\u2019s disease. RSC Med Chem. 2025. https:\/\/doi.org\/10.1039\/d5md00057b.","journal-title":"RSC Med Chem"},{"key":"7695_CR167","unstructured":"Rogers MB, Finally. PET tracers for \u03b1-Synuclein yield signal in idiopathic parkinson\u2019s. Alzforum. 2025. https:\/\/www.alzforum.org\/news\/conference-coverage\/finally-pet-tracers-synuclein-yield-signal-idiopathic-parkinsons. Accessed 06 Dec 2025"},{"key":"7695_CR168","unstructured":"Wester HJ, Yousefi BH. Compounds binding to neuropathological aggregates. WO2016\/001422 A1. 2016."},{"key":"7695_CR169","doi-asserted-by":"publisher","unstructured":"Maurer A, Leonov A, Ryazanov S, Herfert K, Kuebler L, Buss S et al. (11) C Radiolabeling of anle253b: a putative PET tracer for Parkinson\u2019s disease that binds to alpha-synuclein fibrils in vitro and crosses the blood-brain barrier. ChemMedChem. 2020;15:411\u20135. https:\/\/doi.org\/10.1002\/cmdc.201900689.","DOI":"10.1002\/cmdc.201900689"},{"key":"7695_CR170","unstructured":"Shugart J. Spying on \u03b1-Synuclein inclusions: PET tracers inch closer to success. Alzforum. 2023. https:\/\/www.alzforum.org\/news\/conference-coverage\/spying-synuclein-inclusions-pet-tracers-inch-closer-success. Accessed 06 Dec 2025"},{"key":"7695_CR171","doi-asserted-by":"publisher","DOI":"10.3390\/cells14110834","author":"F Capotosti","year":"2025","unstructured":"Capotosti F. A-synuclein PET imaging: from clinical utility in multiple system atrophy to the possible diagnosis of Parkinson\u2019s disease. Cells. 2025. https:\/\/doi.org\/10.3390\/cells14110834.","journal-title":"Cells"},{"key":"7695_CR172","unstructured":"Molette J, Gabellieri E, Darmency V. Bicyclic compounds for diagnosis and therapy. 2017."},{"key":"7695_CR173","unstructured":"Bennacef I, Fawaz MV, Hostetler ED, Mitchell H, Roecker AJ, Shaw AW et al. Alpha-synuclein binders and methods of use. 2024."}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07695-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07695-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07695-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T07:26:36Z","timestamp":1777274796000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07695-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":173,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["7695"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07695-0","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors read and approved the final manuscript for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"N.V. is a co-founder of MedChem Imaging, Inc. K.H. has been involved in collaborative research with MODAG GmbH on the development and evaluation of [\u00b9\u00b9C]MODAG-005. K.H. is also listed as an inventor on the following patent applications: (1)\n                      Novel compounds for the diagnosis\n                      ,\n                      treatment and prevention of diseases associated\n                      , US2023067910A1, filed by MODAG GmbH (published March 2, 2023); and (2)\n                      2-Styrylbenzothiazole derivatives as \u03b1-synuclein binding compounds\n                      , EP4438597A1, filed by the University of Tuebingen, Medical Faculty (published October 2, 2024). The authors have no other relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"In addition to AI assisted copy editing, as defined by the journal guidelines, ChatGPT (OpenAI, Version 4o) was used for literature summarization. All content was critically reviewed and verified by the authors. The authors confirm that the edits reflect their original work, and accept human accountability for the final version.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of artificial intelligence use"}},{"value":"Not Applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}]}}